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ABSTRACT
Objective: Intravenous immunoglobulin preparations have been used in the treatment of primary immunodeficiency for many years. Recently, 
immunoglobulin administration via the subcutaneous route has become popular. Subcutaneously administered immunoglobulin provides 
more stable serum immunoglobulin levels and has a lower incidence of systemic adverse effects than the intravenous route. This method 
increases the quality of the patient’s life by self administration or parental administration at home. Immunoglobulin preparations designed for 
subcutaneous administration have been available in Europe and the US since 2006. Although subcutaneous immunoglobulin preparations are 
not available in Turkey, the subcutaneous administration route has recently been included in the instructions of the three intravenous products 
with 10% concentration. Our aim was to use one of these intravenous immunoglobulin preparations via the subcutaneous route and describe 
its advantages and disadvantages. 
Materials and Methods: Six primary immunodeficiency patients were selected from our clinic. The procedure was described and informed 
consent obtained. They had been treated with intravenous immunoglobulin for the last few years. Their monthly immunoglobulin dosage was 
calculated and roughly divided into weekly doses. The first few administrations took place under medical supervision at the hospital until the 
patients and/or their family learned the procedure. 
Results: They were encouraging with fewer side effects, better life quality and lower infection rates in our small sample of patients. 
Conclusion: In this article, we describe our experience with 6 primary immunodeficiency patients of our clinic in whom we successfully used 
intravenous immunoglobulin preparation via the subcutaneous route.
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INTRODUCTION
The primary immunodeficiency diseases (PIDs) consti-
tute a large group of disease in which patients are born 
missing some of the body’s immune defenses. In 1952, 
Bruton described the first PID, Bruton’s agammaglobu-
linemia, in a boy with recurrent sinopulmonary infec-
tion and pneumonia (1). More than half of PIDs are 
primary antibody deficiencies and the best known are 
common variable deficiency (CVID), Bruton’s agam-
maglobulinemia, selective immunoglobulin deficiencies 
and less frequently hyperimmunoglobulinemia M (HIM) 
syndrome (2). Furthermore, there are combined humoral 
and cellular immunodeficiencies that include severe 
combined immune deficiency, ataxia-telangiectasia (A-T) 
and hyperimmunoglobulinemia E syndrome. The main-
stay treatment for PIDs and combined immunodeficien-
cies are intravenous immunoglobulin (IVIG) therapy and 
prophylactic antibiotics.
Colonel Ogden Bruton who was the first scientist to 
describe PID and was also the first to treat an immune 
deficient patient with immunoglobulin replacement 
therapy via the subcutaneous route (1). Then in 1953 
Janeway et al. preferred immunoglobulin administration 
via the intramuscular route (3). Afterwards for many years, 
immunoglobulin replacement therapy by intramuscular 
immunoglobulin G (IgG) administration was the accepted 
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treatment for PID. However, because of its limitations 
such as pain at the injection sites and the limited volume 
that can be administered, the intravenous route became 
treatment route of choice in the early 1980s (3). 
Although the first subcutaneous immunoglobulin 
(SCIG) therapy attempts with an intramuscular 
preparation were by Berger et al. in the 1980s, this method 
became more popular in the early 2000s (4). SCIG provides 
more stable serum immunoglobulin levels and has a lower 
incidence of systemic adverse effects than the intravenous 
route/ IVIG. This method increases the quality of life by 
self administration or parental administration at home. 
Immunoglobulin preparations designed for subcutaneous 
administration became available in the Europe and 
USA from 2006. Although SCIG preparations are not 
available in Turkey, the subcutaneous administration 
route has recently been included in the instructions of 
the three intravenous commercial products with 10% 
concentration. As described in the literature, we used the 
intravenous preparation via the subcutaneous route (5-7). 
In this study, our aim was to share our SCIG replacement 
therapy experience with an intravenous preparation that 
has been recently approved for subcutaneous usage. 
MATERIALS and METHODS
Six patients with PID were selected for SCIG therapy. 
Of the six patients, 4 were male and 2 were female. The 
mean age was 11.6 years. Four of them had CVID, one 
had HIM syndrome and the other had A-T. Intravenous 
Kiovig® 10% preparation was used for the SCIG with 
subcutaneous administration which has recently been 
included in the instructions. All of our patients were 
taking IVIG before changing to SCIG; there was no patient 
who started replacement therapy directly with SCIG. The 
patients were treated with IVIG (400-600 mg/kg/dose) 
every 2-4 weeks for a few years. After the monthly dosage 
was calculated for IVIG, the same dose was subdivided 
into four weekly doses and given as SCIG weekly which 
was approximately 100 to 150 mg/kg/week. As there was 
no pump for SCIG administration available when we 
started SCIG, the rapid push technique with butterfly 
wing needles (25-Gauge) was used. The abdominal wall, 5 
centimeters below from the umbilicus was preferred for the 
administration. From each site, up to 3 different locations 
around the umbilicus, maximal 35 ml of the intravenous 
preparation was administered in approximately 20 
minutes subcutaneously (1-2 mL/minutes). Other than 
the patients’ immunodeficiency, age, weight, hospital 
admission, IVIG, SCIG dose, duration and interval data, 
we administered the satisfaction questionnaire face-to 
face. The follow-up period was 24 months. The data were 
recorded from patient files retrospectively and written 
informed consent was obtained from all of the patients for 
this presentation.
The data of six of our patients are presented below: 
Case 1
A 19-year-old male was diagnosed with CVID with 
complaints of recurrent lower respiratory tract infections 
for the last 4 years. His IgG and IgA values were 2SD below 
normal for his age. He was treated with IVIG every 3-4 
weeks according to his immunoglobulin levels and clinical 
evaluation. He weighed 78 kilograms and was taking 40 g 
IVIG every 4 weeks. For the last 24 months, he has been 
treated with 10 g SCIG weekly. The first 6 doses were given 
at the hospital under our medical supervision, but now 
he is taking his weekly dose at home (Figure 1). Both he 
and his parents are capable of performing the procedure. 
The demographic, laboratory and clinical findings of the 
patients are shown in Table I.
Case 2
A 10-year-old female patient was diagnosed with 
CVID with low levels of IgG and IgA and complaints of 
recurrent lower respiratory tract infections and frequent 
antibiotic use 3 years ago. She was treated with IVIG every 
2-3 weeks according to her immunoglobulin levels and 
clinical evaluations. She weighed 20 kilograms and was 
taking 10 g IVIG every 2 weeks. Considering her weight 
that was under the 3rd percentile and not having enough fat 
tissue for a subcutaneous procedure, we were concerned 
about the patient’s compliance. For the reason that they 
were living in a small town far from the hospital, she and 
her family were really keen to try SCIG administration. 
Until her mother learned the procedure, the first few doses 
were given at our hospital under medical supervision. For 
the last 20 months she has been treated with 5 g SCIG per 
week. At the beginning, she experienced an urticarial rash 
over the abdomen a couple of times after SCIG was given 
(Figure 2).  
Case 3
A 7-year-old male was diagnosed X-linked HIM 
syndrome with low levels of IgG, IgA and high levels of 
IgM and also low CD40 ligand expression on T-cells by 
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flow cytometry. He was treated with IVIG every 3 weeks 
according to his immunoglobulin levels and clinical 
evaluations. He weighed 19.5 kilograms and was taking 
10 g IVIG every 2 weeks. For 18 months, he had been 
treated with 5 g SCIG weekly. The first 8 doses were given 
at the hospital under medical supervision until his mother 
learned the procedure. At the 4th dose, a mild local reaction 
including swelling, redness, and burning sensation was 
reported at the infusion site and disappeared within 2 
hours without any intervention (Figure 3). 
Case 4
A 13-year-old male presented to our pediatric 
immunology clinic two years ago. He had a history of 
recurrent lower respiratory infections and asthma for 8 
years. After his laboratory results revealed low levels of 
IgG and IgA, he was diagnosed as CVID two years ago. 
He was treated with IVIG every 2 weeks according to 
his immunoglobulin levels and clinical evaluation. He 
weighed 40 kilograms and was taking 20 g IVIG every 2 
weeks. For the last 16 months, he had been treated with 
10 g SCIG weekly. He had not experienced any adverse 
reaction. 
Case 5
An 8-year-old girl was diagnosed with A-T 5 years ago 
with complaints of ataxic movements, telangiectasias and 
recurrent sinopulmonary infections. Past medical history 
revealed encephalitis and Burkitt’s lymphoma followed by 
chemotherapy 2 years ago. She was treated with 10 g IVIG 
every 2 weeks before. She was dependent on a wheelchair 
and therefore after we explained the procedure they 
requested to take SCIG at home. For the last 14 months 
she has been treated with 5 g SCIG per week. There was no 
adverse reaction reported. 
Figure 1. Case 1 administering SCIG 
himself via three lines concurrently.
Figure 2. Urticarial rash at the infusion site observed in case 2. 
Figure 3. Local reaction including swelling, redness and burning 
sensation at the infusion site seen in case 3.
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Case 6
A 13-year-old male was diagnosed as CVID by low 
levels of IgG and IgA when he was treated for encephalitis 
7 years ago. Past medical history included recurrent 
pneumonia, meningitis and epilepsy for 10 years. He 
weighed 35 kilograms and was treated with 30 g IVIG 
every 3 weeks according to his immunoglobulin levels 
and clinical evaluation. For the last 10 months, he has 
been treated with 10 g SCIG weekly. There was no adverse 
reaction observed. 
DISCUSSION
Immunoglobulin replacement therapy is a lifelong 
therapy for PID patients; it therefore needs to be arranged 
individually according to the patient’s preference, clinical 
status and availability of the product. After Bruton used 
SCIG therapy (1), the intramuscular route was preferred 
and finally in the 1980’s the intravenous route became 
the choice of treatment (2,3). Recently, immunoglobulin 
treatment via the subcutaneous route have became 
popular and preferable method. Advantages of SCIG 
Table I. Demographic, laboratory and clinical characteristics of the patients administered SCIG
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CVID: Common variable immunodeficiency. HIM: Hyperimmunoglobulin M syndrome. A-T: Ataxia-Telangiectasia. PFT: Pulmonary 
function test (% predicted).
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include greater independence, no need for vascular 
access; decreased systemic side effects and more stable 
serum IgG levels (8-10). Disadvantages include requiring 
frequent dosing and limitation of the volume that can be 
administered (11-13).
When our patients were evaluated, one patient was 
given SCIG because of poor venous access, one due to 
transportation problems, two at their request and the last 
two due to our recommendations (Table I). All of our 
patient’s parents reported that their children had lower 
infection rates and better quality of life than before. Except 
for case 2 and case 5, four of our patients had no hospital 
admissions after SCIG therapy. When we interviewed 
the second case’s mother, she emphasized that once her 
child became healthier with SCIG they spent more time in 
public places and therefore she suffered an infection. Some 
published studies suggested that each PID patient requires 
personal immunoglobulin levels to prevent breakthrough 
infections and therefore our case might need SCIG dose 
adjustment to prevent infections (13). Gardulf et al. 
reported that SCIG home therapy ensured better health, 
improved social/school functioning, reduced emotional 
stress and limitations on personal time for parents, and 
created fewer limitations on family activities (8). In our 
cases the most dramatic change was seen in Case 1. Before 
the SCIG therapy, he did not have a social life and stayed 
home all day, but now he started to work in our hospital’s 
human resources department. In addition, he had his best 
pulmonary function test results ever after SCIG therapy. 
We could not calculate the overall effect of SCIG on 
spirometry results, since some of our patients were not 
cooperative during pulmonary function testing (Table I). 
All of our patients have had more stable IgG levels 
after SCIG, and we did not observe any low through 
levels of serum IgG as we experienced during intravenous 
administration. Although serum IgG measurement 
alone is not a sufficient marker for efficacy, we observed 
slightly increased mean IgG levels. The mean serum 
immunoglobulin levels before and after SCIG are 
summarized in Table I. We switched from the intravenous 
to the subcutaneous route with the same preparation 
which was well-tolerated by the patients previously. It 
seems that our patients were receiving a little higher doses 
for SCIG infusion  because their IVIG dose was also higher 
due to their lung disease (bronchiectasis) at the beginning. 
The SCIG dose of the patients who previously used IVIG 
in this study was not calculated according to a conversion 
formula, assuming the SCIG dose as about 1.37-fold of the 
IVIG dose. As commonly accepted, we simply divided the 
total monthly calculated IVIG dose into 4 for every week 
SCIG application. Although two of our cases reported 
a mild local reaction at the infusion site, there were no 
serious side effects observed. Until now there have been no 
discontinuations because of tolerability problems. Unlike 
IVIG, there are very few systemic adverse effects with SCIG 
in published studies (8-11). As reported in other studies, 
we reported only mild local adverse reactions (Figure 2, 3).
Another aspect is the cost. Although it is controversial, 
most studies have shown that SCIG has lower cost than 
IVIG because of the lack of facility and nursery charges 
(14). Besides hospital charges, the transportation cost 
is another issue for low income families and wheelchair 
dependent patients (15,16). Moreover, subcutaneous 
pumps were not available in our country when we started 
SCIG; we therefore used the rapid push technique in our 
patients and overall costs were free of pump purchase 
prices.
We only observed local adverse reactions over the 
abdomen a few times in some of the cases at the beginning 
of the treatment, as reported in the literature (8-11,17); 
otherwise there was no systemic complications. Local 
reactions including urticaria, swelling, redness and 
burning sensation at the infusion site as seen in case 1 and 
case 3 (Figure 2, 3) were encountered. They did not require 
any treatment and resolved in a couple of hours. 
CONCLUSION
All of our patients’ complaints decreased after SCIG 
use. In addition, our patients’ immunoglobulin levels were 
more stable after SCIG was started. All patients reported 
they wished to continue their treatments with SCIG 
administration. Our clinical experience showed that the 
subcutaneous route is safer, clinically more effective and 
has fewer side effects than the intravenous route. Although 
optimistic results have been reported with SCIG in the 
literature, further studies done at multiple centers and 
with more patients in our country, Turkey, will provide 
more information about SCIG administration benefits.
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